A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT ID: NCT06298565
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
680 participants
OBSERVATIONAL
2024-11-04
2034-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
NCT04980495
Efgartigimod Expanded Access for Generalized Myasthenia Gravis
NCT04777734
Seronegative Myasthenia Gravis - Efgartigimod IV
NCT06587867
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06860633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
efgartigimod cohort
patients treated with efgartigimod
efgartigimod
efgartigimod
non-efgartigimod cohort
patient treated with other MG medication
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
efgartigimod
efgartigimod
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have provided appropriate written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
argenx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,
San Francisco, California, United States
SFM Clinical Research, LLC
Boca Raton, Florida, United States
University of Florida College of Medicine Jacksonville
Jacksonville Beach, Florida, United States
Medsol Clinical Research Center Inc
Port Charlotte, Florida, United States
BayCare Health System, Inc. St Anthony's Hospital
St. Petersburg, Florida, United States
Prairie Education and Research Cooperative and HSHS Medical Group
O'Fallon, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Norton Neuroscience Institute
Louisville, Kentucky, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Colorado Hospital
Portland, Oregon, United States
Medical University of South Carolina
Charleston, South Carolina, United States
National Neuromuscular Research Institute
Austin, Texas, United States
BCN Research, LLC - Gamma Therapeutic Center
Greenfield, Wisconsin, United States
Kepler Universitätsklinikum, Universitätsklinik für Neurologie, Med Campus III
Linz, , Austria
UZ Leuven (University Hospitals Leuven)
Leuven, , Belgium
Klinikum Altenburger Land GmbH
Altenburg, , Germany
St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum
Bochum, , Germany
Klinikum Christophsbad
Göppingen, , Germany
Georg-August-Universität Göttingen
Göttingen, , Germany
Klinikum Oberberg
Gummersbach, , Germany
Universitätsklinikum Jena
Jena, , Germany
Universitätsklinikum Würzburg
Würzburg, , Germany
Piazza OMS - Organizzazione Mondiale della Sanità
Bergamo, , Italy
Ospedale Bellaria - Clinica Neurologica
Bologna, , Italy
Azienda Ospedaliera di Rilievo Nazionale Cardarelli
Napoli, , Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Hospital Universitari Vall d'Hebron, Unitat de Malalties Neuromusculars, Servei de Neurologia
Barcelona, , Spain
Hospital Universitari de Bellvitge
Barcelona, , Spain
Hospital Clinico Universitario San Carlos
Madrid, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARGX-113-PASS-2208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.